Health Trials

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

ConditionDiabetes Mellitus, Type 2
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorEli Lilly and Company

About this trial

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Eligibility criteria

Qualifiers

Have type 2 diabetes

Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening

Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive

Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Disqualifiers

Have type 1 diabetes

Trial design

Treatments tested in this trial

  • LY3938577
  • Degludec

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov